Zhuang Tian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7726894/publications.pdf

Version: 2024-02-01

64	988	471509 17	526287 27
papers	citations	h-index	g-index

79	79	79	1529
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2016, 16, 129.	1.7	94
2	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. International Journal of Cardiology, 2017, 236, 432-437.	1.7	81
3	The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 2.	3.3	68
4	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. European Respiratory Journal, 2019, 53, 1800081.	6.7	49
5	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. Autoimmunity Reviews, 2016, 15, 250-257.	5.8	45
6	Cisplatin-induced cardiotoxicity with midrange ejection fraction. Medicine (United States), 2018, 97, e13807.	1.0	39
7	Antiâ€“Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosusâ€“Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2015, 67, 2394-2402.	5.6	34
8	Association Between Subclinical Hypothyroidism and Blood Pressure - A Meta-Analysis of Observational Studies. Endocrine Practice, 2014, 20, 150-158.	2.1	32
9	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. , 2020, 11, 1623.		29
10	Pulmonary arterial hypertension associated with primary SjÃ¶gren's syndrome: a multicentre cohort study from China. European Respiratory Journal, 2020, 56, 1902157.	6.7	27
11	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTARâ€PAH study: Baseline characteristics and risk factors. International Journal of Rheumatic Diseases, 2019, 22, 921-928.	1.9	26
12	Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Physics, 2021, 8, 3.	2.7	25
13	Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension. BioMed Research International, 2015, 2015, 1-14.	1.9	23
14	Clinical correlates and prognostic values of pseudoinfarction in cardiac light-chain amyloidosis. Journal of Cardiology, 2016, 68, 426-430.	1.9	23
15	Intracardiac thrombus in patients with Behcetâ€™s disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. Clinical Rheumatology, 2016, 35, 2501-2507.	2.2	23
16	Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. Infection, Genetics and Evolution, 2020, 85, 104419.	2.3	23
17	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2021, 22, 111-118.	1.2	22
18	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary SjÃ¶gren's syndrome. International Journal of Rheumatic Diseases, 2018, 21, 1068-1075.	1.9	21

#	Article	IF	Citations
19	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. Clinical Rheumatology, 2018, 37, 979-985.	2.2	19
20	CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure. Journal of Experimental Medicine, 2022, 219, .	8.5	18
21	Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 66-73.	3.0	17
22	The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLEâ€PAH. FASEB Journal, 2021, 35, e22044.	0.5	15
23	Left and right ventricular myocardial deformation and late gadolinium enhancement: incremental prognostic value in amyloid light-chain amyloidosis. Cardiovascular Diagnosis and Therapy, 2020, 10, 470-480.	1.7	14
24	Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. Orphanet Journal of Rare Diseases, 2019, 14, 251.	2.7	13
25	Risk Factors and Prognostic Role of Left Atrial Enlargement in Patients with Cardiac Light-Chain Amyloidosis. American Journal of the Medical Sciences, 2016, 351, 271-278.	1.1	12
26	Transesophageal echocardiography to assess mitral valve movement and flow during long term cardiopulmonary resuscitation: How cardiac effects fade with time. International Journal of Cardiology, 2016, 223, 693-698.	1.7	11
27	Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients. Frontiers of Medicine, 2019, 13, 259-266.	3.4	11
28	Burnout and Well-Being Among Medical Professionals in China: A National Cross-Sectional Study. Frontiers in Public Health, 2021, 9, 761706.	2.7	11
29	Anomalous Origin of the Left Coronary Artery from the Pulmonary Artery Detected by Echocardiography in an Asymptomatic Adult. Internal Medicine, 2013, 52, 233-236.	0.7	10
30	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogrenâ€™s syndrome: a retrospective cohort study. Clinical Rheumatology, 2019, 38, 477-485.	2.2	10
31	Inflammation in SLE-PAH: good news or not?. Annals of the Rheumatic Diseases, 2019, 78, e135-e135.	0.9	10
32	Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 36-44.	3.0	10
33	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. Heart Lung and Circulation, 2019, 28, 1655-1663.	0.4	9
34	The Role of Antiâ€“U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Diseaseâ€“Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. Arthritis and Rheumatology, 2016, 68, 1788-1789.	5.6	8
35	Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapyã€€â€• A Single-Center Cohort Study of 227 Patients â€•. Circulation Journal, 2019, 83, 775-782.	1.6	8
36	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. Hypertension, 2020, 76, 1161-1168.	2.7	8

#	Article	IF	Citations
37	Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	1.5	8
38	Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis patients from EUSTAR data in China. Clinical and Experimental Rheumatology, 2015, 33, S106-10.	0.8	8
39	Optimal Oral Antithrombotic Regimes for Patients with Acute Coronary Syndrome: A Network Meta-Analysis. PLoS ONE, 2014, 9, e90986.	2.5	7
40	Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. Clinical and Experimental Rheumatology, 2016, 34, 291-5.	0.8	7
41	Hemodynamic parameters obtained by transthoracic echocardiography and right heart catheterization: a comparative study in patients with pulmonary hypertension. Chinese Medical Journal, 2011, 124, 1796-801.	2.3	6
42	Successful Treatment of Type 1 Cryoglobulinemic Vasculitis With Cardiac Involvement. Canadian Journal of Cardiology, 2018, 34, 343.e1-343.e3.	1.7	5
43	Is it possible to apply the treat-to-target strategy in primary SjÃ¶grenâ€™s syndrome-associated pulmonary arterial hypertension?. Clinical Rheumatology, 2018, 37, 2989-2998.	2.2	5
44	Physiciansâ€™ knowledge on specific rare diseases and its associated factors: a national cross-sectional study from China. Orphanet Journal of Rare Diseases, 2022, 17, 120.	2.7	4
45	CBLN2 rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus. Chinese Medical Journal, 2018, 131, 3020-3021.	2.3	3
46	Evaluating heart function in patients with POEMS syndrome. Echocardiography, 2019, 36, 1997-2003.	0.9	3
47	Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation. Stem Cell Research, 2020, 49, 102022.	0.7	3
48	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 618486.	2.6	3
49	Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis. Frontiers in Cardiovascular Medicine, 2020, 7, 597472.	2.4	3
50	Importance of endomyocardial biopsy in unexplained cardiomyopathy in China: a report of 53 consecutive patients. Chinese Medical Journal, 2010, 123, 864-70.	2.3	3
51	Disease Activity Is Related to Acute Response to Vasodilator in Pulmonary Artery Hypertension Associated With Systemic Lupus Erythematosus. Circulation Journal, 2014, 78, 1240-1244.	1.6	2
52	How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. Expert Opinion on Pharmacotherapy, 2021, 22, 557-563.	1.8	2
53	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review. Lupus Science and Medicine, 2022, 9, e000636.	2.7	2
54	Recurrent Variant Angina Pectoris due to Behcet's Syndrome. Internal Medicine, 2011, 50, 2587-2589.	0.7	1

#	Article	IF	Citations
55	Danon disease presenting as severe myocardial hypertrophy. European Heart Journal, 2011, 32, 2375-2375.	2.2	1
56	Mycobacterium Avium Spindle Cell Pseudotumor in the Left Ventricle. Circulation: Cardiovascular Imaging, 2019, 12, e009604.	2.6	1
57	Right ventricular systolic function is associated with health-related quality of life: a cross-sectional study in community-dwelling populations. Annals of Translational Medicine, 2021, 9, 640-640.	1.7	1
58	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. Pulmonary Circulation, 2021, 11, 1-8.	1.7	1
59	A retrospective study of ultrahigh-risk (Mayo 2004 stage IIIb) AL amyloidosis and identification of predictors related to extremely early death. Leukemia and Lymphoma, 2022, 63, 1758-1761.	1.3	1
60	Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to BehÃ§et's disease. Clinical and Experimental Rheumatology, 2016, 34, S26-S33.	0.8	1
61	Infective Endocarditis in a Patient with Incomplete Shone's Anomaly. Internal Medicine, 2012, 51, 2835-2836.	0.7	0
62	Lymphoma in the heart:. European Heart Journal Cardiovascular Imaging, 2015, 16, 830-830.	1.2	0
63	33â€…Composite goals plus inflammation: further risk assessment for systemic lupus erythematosus associated pulmonary arterial hypertension in CSTAR-PAH cohort. , 2019, , .		0
64	Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly. Journal of Geriatric Cardiology, 2020, 17, 793-796.	0.2	0